Skip to main content
Evidence: BCognitive EnhancementNeuroprotection

Cerebrolysin: Benefits, Dosage & FDA Status

Cerebrolysin (porcine brain peptide complex)

A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.

FDA Status

Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia

Typical Dose

Trial range: 5–30 mL daily (intravenous infusion)

Evidence Grade

BLimited clinical + robust preclinical evidence

Half-Life

Mixture (varies by component)

Routes of Administration

intravenous, intramuscular

First Synthesized

1970s

Clinics Indexed

41 providers have offered Cerebrolysin in our tracked directory.

Mechanism of Action

Mixture of small peptides and amino acids exerting neurotrophic effects similar to endogenous BDNF/NGF; activates Akt/MAPK pathways.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.

Reported Side Effects

  • •Flushing
  • •Sweating
  • •Hypersensitivity (rare)

Contraindications

  • ⚠Severe renal impairment
  • ⚠Status epilepticus
  • ⚠Pregnancy

Cerebrolysin vs Other Peptides

Cerebrolysin vs Semax→Cerebrolysin vs Selank→Cerebrolysin vs DSIP→Cerebrolysin vs ARA-290→Cerebrolysin vs Dihexa→Cerebrolysin vs Pinealon→

Regulatory & Safety Context

FDA status: Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on Cerebrolysin. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 31774552

Last reviewed: 2026-04-30

Related Peptides

Semax

B

A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.

Dihexa

C

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

Selank

B

A synthetic analog of tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems to reduce anxiety without sedation.

DSIP

C

A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.

ARA-290

B

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

Pinealon

C

A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.

← Back to all peptides